Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling

被引：0
|
作者：
Liu, Stephanie N. [1 ]
Chan, Phyllis [1 ]
Marchand, Mathilde [2 ]
Herraez-Baranda, Luis [3 ]
Bruno, Rene [4 ]
Chanu, Pascal [5 ]
Wu, Benjamin [1 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Certara Strateg Consulting, Paris, France
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Genentech Roche, Marseille, France
[5] Genentech Roche, Lyon, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.99
引用
收藏
页码：E44 / E44
页数：1
相关论文
共 42 条
  • [31] Evaluation of subcutaneous bioavailability of CNTO 3157 in healthy volunteers using a two-compartment population PK model with additional non-linear clearance function
    Han, Chao
    Mayer, Christina L.
    Jiao, Qun
    Davis, Hugh M.
    Heald, Donald L.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S19 - S19
  • [32] Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach
    Liu, Qingxia
    Huang, Huiping
    Xu, Baohua
    Li, Dandan
    Liu, Maobai
    Shaik, Imam H.
    Wu, Xuemei
    PHARMACEUTICS, 2022, 14 (05)
  • [33] A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration
    Berkhout, Jan
    Fairman, Dave
    van Noort, Martijn
    van Steeg, Tamara J.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025, 14 (01): : 17 - 27
  • [34] Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: Stage 1 results of the phase III SABRINA study
    Davies, A. J.
    Merli, F.
    Mihaljevic, B.
    Siritanaratkul, N.
    Solal-Celigny, P.
    Boehnke, A.
    Berge, C.
    McIntyre, C.
    Barrett, M.
    MacDonald, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 7 - 8
  • [35] ENCOURAGING PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) RESULTS OF SUBCUTANEOUS (SC) BLINATUMOMAB IN RELAPSED OR REFRACTORY (R/R) INDOLENT NON-HODGKIN'S LYMPHOMA (I-NHL) AND R/R ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS (PTS) INDICATE THAT PATIENT CONVENIENT SC DOSING IS A VIABLE ALTERNATIVE TO CONTINUOUS INTRAVENOUS INFUSION (CIV) DOSING.
    Wong, H.
    Chandra, F.
    Zugmaier, G.
    Gordon, P.
    Zeng, Y.
    Doshi, S.
    Dutta, S.
    Upreti, V.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S79 - S79
  • [36] A CLINICAL STUDY TO INVESTIGATE PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD), EFFICACY, AND SAFETY OF TOCILIZUMAB (TCZ) AFTER SUBCUTANEOUS (SC) ADMINISTRATION WEEKLY (QW) OR EVERY TWO WEEKS (Q2W) IN PATIENTS (pts) WITH RHEUMATOID ARTHRITIS (RA).
    Zhang, X.
    Chen, Y.
    Fettner, S.
    Anzures-Cabrera, J.
    Gott, T.
    Grimsey, P.
    Unsworth, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S117 - S117
  • [37] Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)
    Davies, Andrew
    Merli, Francesco
    Mihaljevik, Biljana
    Siritanaratkul, Noppadol
    Solal-Celigny, Philippe
    Boehnke, Axel
    Berge, Claude
    McIntyre, Christine
    Barrett, Martin
    Macdonald, David
    BLOOD, 2012, 120 (21)
  • [38] Evaluation of a drug induced-QT/QTc prolongation in the presence of the drug induced changes in heart rate by using population PK/PD modeling approach: sibenadet experience.
    Li, J.
    Birmingham, B.
    Mosqueda-Garcia, R.
    Sander, N.
    Newbold, P.
    Sager, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S42 - S42
  • [39] Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose
    Wei, Andrew H.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Loo, Sun
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Xu, Siyan
    Liao, Serena
    Stein, Andrew
    Khanshan, Fariba
    Naidu, Purushotham
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael L.
    Sun, Haiying
    Brunner, Andrew M.
    Borate, Uma
    BLOOD, 2020, 136
  • [40] Exploratory evaluation of the potential predictors for dose-limiting toxicities (DLTs) in patients treated with Ecteinascidin-743 (ET-743) as a 24-h intravenous (iv) infusion every 3 weeks and its relationship to pharmacokinetics (PK).
    López-Lázaro, L
    Guzmán, C
    Taamma, A
    Cvitkovic, E
    Misset, JL
    Brain, E
    Beijnen, JH
    Jimeno, J
    CLINICAL CANCER RESEARCH, 1999, 5 : 3791S - 3791S
12345